CHRYSALIS-2 ✨ Amivantamabe + Lazertinibe em CPNPC com mutações atípicas de EGFR (≤2L) 👥 N=105 (16m) 🧬 G719X 56% | L861X 26% | S768I 23% 📊 ORR 52% | mDoR 14.1m | mPFS 11m ➡️ Atividade robusta em mutações atípicas de EGFR🚀.

In 1928, Alexander Fleming discovered the mould he was working with produced a substance that could kill many common bacteria. He called this new, exciting substance "mould juice". Only after a couple of months did he name it penicillin. #AntimicrobialAwarenessWeek #WAAW2025

To all researchers, clinicians, patients: we invite you to complete a brief survey reviewing consensus statements on PROMs in clinical trials for #LungCancer. https://t.co/22r7emYNzx @IASLC @NarjustFlorezMD @DoctorJSpicer @DrJNaidoo @stephanieplsaw @jillfeldman4

Precision oncology in Lung Cancer preceptorship is 🔛 #lungcancer #targetedtherapy #precisiononcology

Great day for a neuro and thoracic oncology 🙋🏼‍♀️. An FDA “combo” approval. 🫁Tarlatamab & 🧠selumetinib & 🫁sevabertinib ❤️❤️❤️

The best Oncology meeting in Brazil! @SBOC_Oncologia

“Sales have been banned since 2009, but … the use of electronic cigarettes has increased by 600% in Brazil between 2018 and 2023. Are we really going to wait 20 years — and waste two more generations — before taking action?!” 🔗 https://t.co/6zDScOil0j

We’re looking for passionate, energetic clinicians who are excited to become the best medical oncologists in Brazil! 😝 #idor #oncologyresidence #medicaloncology @Institutodor

Who else also needs Google Maps, Waze, or a GPS to find their way around #ESMO25?😂

🫁 FLAURA2: Exploratory OS analysis. #PasiJanne Survival benefit with osimertinib + platinum-pemetrexed vs monotherapy across poor-prognosis subgroups (CNS mets, L858R, plasma EGFRm, TP53-altered). Reinforces combination as 1L standard for EGFRm NSCLC. @myESMO #ESMO25 #CánCare

This regimen seems to be less toxic than the old one however remains to be seen if immunotherapy and chemo are better or not? #lungcancer #lcsm

📍📍HARMONi-6: Ivos/ChT vs ChT/IO in 1L advanced sq-NSCLC ✅ mPFS 11.14 vs 6.9 mo HR 0.60 - ✅ Higher ORR and mDOR ✅ Low VEGF-rel AEs First phase 3 study to improve PFS outcomes compared to SoC- will this translate to an OS improvement? #ESMO25 #ESMOAmbassadors

Dr. Shun Lu delivers HARMONi-6 results at #ESMO25: first line ivonescimab + chemotherapy vs tislelizumab (PD-1, approved by China, EMA) + chemo for advanced squamous NSCLC. Chemotherapy + immunotherapy is our standard of care but squamous outcomes remain poor. #ESMOAmbassadors

🆙 #ESMO25 🇩🇪 🔥#LCSM Mini Oral NSCLC mets ☑️Firmonertinib: Phase II study of firmonertinib in pts with previously treated advanced/metastatic NSCLC with EGFR ex20ins ☑️ ORR 44.3%, mPFS 8.3m, mOS 21.2m 🎙️ Dr. Ying Liu @OncoAlert @myESMO @Larvol

🫁 GBOT na ESMO25 📚 ALINA Trial - atualização 4 ano 📊 DFS II–IIIA: HR 0,36 (95%CI 0,23–0,56); 4y: 74,5% vs 46,3% 📊 DFS IB–IIIA (ITT): HR 0.35; 4y: 75.5% vs 47.0% 🧠 CNS-DFS: HR 0,37; 90,4% vs 76,1% 💫 Tendência favorável em OS (98,4% vs 92,4%)

◼️◼️◼️[_][_] LOADING…. #ESMO25

O Governo Federal anunciou recentemente a regulamentação da Lei da Pesquisa Clínica. A legislação pretende trazer mais segurança jurídica para o setor, atraindo investimentos em inovação e impulsionando uma área estratégica para o desenvolvimento científico e industrial do país.

Hackathon @SBOC_Oncologia is on! Code4cancer - let’s hacker cancer. We are searching for innovative ideas to improve access to cancer prevention. #hackathon #cancerprevention @HackathonBR

Esta iniciativa é uma parceria entre a Maurício de Sousa Produções e a SBOC, a SBM, a SBCO, a SBRT, a SBGM, o CBR e a Febrasgo.